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Paclitaxel (PTX) is one of the most effective anticancer agents. In clinical practice, however, high incidences of adverse reactions of
the drug, for example, neurotoxicity, myelosuppression, and allergic reactions, have been reported. NK105, a micellar nanoparticle
formulation, was developed to overcome these problems and to enhance the antitumour activity of PTX. Via the self-association
process, PTX was incorporated into the inner core of the micelle system by physical entrapment through hydrophobic interactions
between the drug and the well-designed block copolymers for PTX. NK105 was compared with free PTX with respect to their in
vitro cytotoxicity, in vivo antitumour activity, pharmacokinetics, pharmacodynamics, and neurotoxicity. Consequently, the plasma area
under the curve (AUC) values were approximately 90-fold higher for NK105 than for free PTX because the leakage of PTX from
normal blood vessels was minimal and its capture by the reticuloendothelial system minimised. Thus, the tumour AUC value was 25-
fold higher for NK105 than for free PTX. NK105 showed significantly potent antitumour activity on a human colorectal cancer cell
line HT-29 xenograft as compared with PTX (Po0.001) because the enhanced accumulation of the drug in the tumour has occurred,
probably followed by its effective and sustained release from micellar nanoparticles. Neurotoxicity was significantly weaker with
NK105 than with free PTX. The neurotoxicity of PTX was attenuated by NK105, which was demonstrated by both histopathological
(Po0.001) and physiological (Po0.05) methods for the first time. The present study suggests that NK105 warrants a clinical trial for
patients with metastatic solid tumours.
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Paclitaxel (PTX) is one of the most useful anticancer agents known
for various cancers including ovarian, breast, and lung cancers
(Carney, 1996; Khayat et al, 2000). However, PTX has serious
adverse effects, for example, neutropenia and peripheral sensory
neuropathy. In addition, anaphylaxis and other severe hypersensi-
tive reactions have been reported to develop in 2–4% of patients
receiving the drug even after premedication with antiallergic
agents; these adverse reactions have been attributed to the mixture
of Cremophor EL and ethanol, which was used to solubilise PTX
(Weiss et al, 1990; Rowinsky and Donehower, 1995). Of the adverse
reactions, neutropenia can be prevented or managed effectively by
administering a granulocyte colony-stimulating factor. On the
other hand, there are no effective therapies to prevent or reduce
nerve damage, which is associated with peripheral neuropathy
caused by PTX; therefore, neurotoxicity constitutes a significant
dose-limiting toxicity of the drug (Rowinsky et al, 1993;
Wasserheit et al, 1996).
The above problems of PTX have been attributed to its low
therapeutic indices and limited efficacy due to the nonselective
nature of its therapeutic targets and its inability to accumulate
selectively in cancer tissue. Therefore, there is an urgent need to
develop modalities by which cytotoxic drugs can selectively target
tumour tissue and effectively act on cancer cells in the scene. The
roles of drug delivery systems (DDSs) have drawn attention in this
context. Drug delivery systems are based on two main principles:
active and passive targetings. The former refers to the development
of monoclonal antibodies directed against tumour-related mole-
cules that allow targeting of the tumour because of specific binding
between the antibody and its antigen. However, the application of
Received 27 October 2004; revised 26 January 2005; accepted 31
January 2005; published online 22 March 2005
*Correspondence: Dr Y Matsumura, Investigative Treatment Division,
National Cancer Center Research Institute East, 6-5-1 Kashiwanoha,
Kashiwa, Chiba 277-8577, Japan; E-mail: yhmatsum@east.ncc.go.jp
British Journal of Cancer (2005) 92, 1240–1246
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sDDSs using monoclonal antibodies is restricted to tumours
expressing high levels of related antigens.
Passive targeting is based on the so-called enhanced perme-
ability and retention (EPR) effect (Matsumura and Maeda, 1986;
Maeda et al, 2000). The EPR effect consists in the pathophysio-
logical characteristics of solid tumour tissue: hypervascularity,
incomplete vascular architecture, secretion of vascular perme-
ability factors stimulating extravasation within cancer tissue, and
absence of effective lymphatic drainage from tumours that
impedes the efficient clearance of macromolecules accumulated
in solid tumour tissues.
Several techniques to maximally use the EPR effect have been
developed, that is, modification of drug structures and develop-
ment of drug carriers. The first micelle-forming polymeric drug
developed was polyethylene glycol (PEG)-polyaspartate block
copolymer conjugated with doxorubicin (DXR) (Yokoyama et al,
1990; Yokoyama et al, 1991; Kataoka et al, 1993). PEG constituted
the outer shell of the micelle, which conferred a stealth property on
the drug that allowed the micellar drug preparations to be less
avidly taken up by the reticuloendothelial system (RES) and to be
retained in the circulation for a longer time. Prolonged circulation
time and the ability of polymeric micelles to extravasate through
the leaky tumour vasculature were expected to result in the
accumulation of DXR in tumour tissue due to the EPR effect
(Kwon et al, 1994; Yokoyama et al, 1999). A clinical trail of
micellar DXR, NK911, is now underway (Nakanishi et al, 2001;
Hamaguchi et al, 2003). Recently, we succeeded in constructing
NK105, a polymeric micelle carrier system for PTX, which
conferred on PTX a passive targeting ability based on the EPR
effect. In the present paper, we describe the details and
characteristics of NK105. We also discuss differences between
NK105 and other DDS formulations containing PTX.
MATERIALS AND METHODS
Materials
PTX was purchased from Mercian Corp. (Tokyo, Japan). All other
chemicals were of reagent grade. Following cell lines, MKN-45,
MKN-28, HT-29, DLD-1, HCT116, TE-1, TE-8, PC-14, PC-14/TXT,
H460, MCAS, OVCAR-3, AsPC-1, PAN-9, PAN-3, and MCF-7 cells
were purchased from American Type Culture Collection. Colon 26
cells were dispensed from the Japan Foundation for Cancer
Research (Tokyo, Japan). Female BALB/c nu/nu mice were
purchased from SLC (Shizuoka, Japan). Female CDF1 mice and
IGS rats were purchased from Charles River Japan Inc. (Kanagawa,
Japan).
All animal procedures were performed in compliance with the
guidelines for the care and use of experimental animals, which had
been drawn up by the Committee for Animal Experimentation of
the National Cancer Center; these guidelines meet the ethical
standards required by law and also comply with the guidelines for
the use of experimental animals in Japan.
NK105, a PTX-incorporating micellar nanoparticle
formulation
NK105 is a PTX-incorporating ‘core-shell-type’ polymeric micellar
nanoparticle formulation. Polymeric micellar particles were
formed by facilitating the self-association of amphiphilic block
copolymers in an aqueous medium. Novel amphiphilic block
copolymers, namely NK105 polymers, were designed for PTX
entrapment. NK105 polymers were constructed using PEG as the
hydrophilic segment and modified polyaspartate as the hydro-
phobic segment. Carboxylic groups of polyaspartate block were
modified with 4-phenyl-1-butanol by esterification reaction,
consequently the half of the groups were converted to 4-phenyl-
1-butanolate. Via the self-association process, PTX was incorpo-
rated into the inner core of the micelle system by physical
entrapment through hydrophobic interactions between the drug
and specifically well-designed block copolymers for PTX.
Pharmacokinetics and pharmacodynamics of PTX and
NK105
Colon 26 tumour-bearing CDF1 mice aged 8 weeks were given
intravenously (i.v.) via the tail vein PTX 50 and 100mgkg
 1 or
NK105 at corresponding PTX-equivalent doses. Mice were killed at
5 and 30min, as well as 2, 6, 24, and 72h after injection. Blood was
collected, and tumours were removed; plasma and tumours
obtained were then stored at  201C until the analysis. Each time
point for collection represented three samples from three different
mice. PTX was extracted from plasma obtained by deproteinisation
using acetonitrile, followed by liquid–liquid extraction with
t-butylmethylether. Tumours obtained were homogenised in
0.5% acetic acid, and the resultant homogenate was deproteinised
and extracted according to the same method as that used for
plasma. The blood and tumour extracts were analysed for PTX by
liquid chromatography/tandem mass spectrometry. Reversed-
phase column-switching chromatography was conducted using
an ODS column and detection was enabled by electrospray
ionisation of positive mode. The mean plasma and tumour
concentrations of PTX at each sampling point were calculated
for both PTX and NK105. Pharmacokinetic modelling was
completed using a WinNonlin Standard software version 3.1
(Pharsight Corp., California, USA).
In vitro cytotoxicity
Various human cancer cell lines were evaluated in the present
study. The cell lines were maintained in monolayer cultures in
Dulbecco’s modified Eagle’s medium containing 10% (vv
 1) foetal
calf serum and 600mgl
 1 glutamine. WST-8 Cell Counting Kit-8
(Dojindo, Kumamoto, Japan) was used for the cell proliferation
assay. In all, 2000 cells of each cell line in 90ml of culture medium
were plated in 96-well plates and were then incubated for 24h at
371C. Serial dilutions of PTX or NK105 in a volume of 10ml were
added, and the cells were incubated for 48 or 72h. All data were
expressed as mean7s.e. of triplicate cultures. The data were then
plotted as a percentage of the data from the control cultures, which
were treated identically to the experimental cultures, except that
no drug was added.
Evaluation of the antitumour activity of PTX and NK105
The antitumour activity of PTX and NK105 was evaluated using
nude mice implanted with a human colonic cancer cell line, HT-29.
One million tumour cells of HT-29 were inoculated at a
subcutaneous (s.c.) site on the back skin of BALB/c female nude
mice aged 6 weeks. When tumour size reached approximately
5–8mm in diameter, mice were randomly allocated to the PTX
administration group, NK105 administration group, and control
administration group, each of which was made up of five animals.
Each treatment was carried out as follows: free PTX group
was administered at a dose of 25, 50, or 100mgkg
 1; NK105
group was with same PTX-equivalent doses; and in control group,
animals were given saline. Mice were administered a single i.v.
injection of PTX or NK105 weekly for 3 weeks. The antitumour
activity of PTX and NK105 was evaluated by measuring tumour
size (a b, where a is the major diameter and b is the minor
diameter) at various time points after injection. Changes in body
weight were also monitored for mice, which were used in the
present study.
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The severity of neurotoxicity was assessed both electrophysiolo-
gically and histologically. Under intraperitoneal ketamine anaes-
thesia (40mgkg
 1), rats were given a single i.v. injection of PTX
(7.5mgkg
 1), NK105 (a PTX-equivalent dose of 7.5mgkg
 1), or
5% glucose weekly for 6 weeks. All the solutions were administered
through the jugular vein exposed via a small incision in the neck.
Electrophysiological measurements were conducted 1 day before
the first dosing and on day 6 after the final dosing. For
electrophysiological recording, rats were anaesthetised by the
intraperitoneal injection of pentobarbital 40mgkg
 1. Electrical
stimuli were given peripherally, and caudal sensory nerve action
potentials (caudal SNAPs) were recorded centrally from the tail.
The amplitude of each waveform was calculated by measuring the
caudal SNAP from the top peak to the bottom peak. Variations in
the amplitude after the 6th weekly administration of the solutions
were determined.
For light microscopy, rats were killed after electrophysiological
recordings. Subsequently, a segment of the sciatic nerve was
carefully removed, and embedded in paraffin. Sections (2mm
thick) were stained with haematoxylin and eosin (H & E) before
examination under light microscopy to evaluate the degenerative
changes of myelinated nerve fibres.
Statistical analysis
The data of therapeutic efficacy was expressed as mean7s.e.m.
The statistical significance of differences in therapeutic efficacy
between two administration groups was calculated by means of
repeated measures (analysis of variance). The statistical signifi-
cance of the differences in neurotoxic activity between two
administration groups was calculated using the Student’s t-test
on the closed testing procedure. The histopathological impairment
was scored in five grades. The statistical significance of the
differences in histopathological impairment between two admin-
istration groups was calculated using the Wilcoxon’s rank-sum test
on the closed testing procedure. All data were calculated with
software StatView, version 5 (ABACUS Concepts, Berkeley, CA,
USA). A value of Po0.05 was considered statistically significant.
RESULTS
Preparation and characterisation of NK105
To construct NK105 micellar nanoparticles (Figure 1A), block
copolymers consisting of PEG and polyaspartate, the so-called PEG
polyaspartate described previously (9, 11, 13, 14), were used. PTX
was incorporated into polymeric micelles formed by physical
entrapment utilising hydrophobic interactions between PTX and
the block copolymer polyaspartate chain. After screening of many
candidate substances, 4-phenyl-1-butanol was employed for the
chemical modification of the polyaspartate block to increase its
hydrophobicity. Treating with a condensing agent, 1,3-diisopro-
pylcarbodiimide, the half of carboxyl groups on the polyaspartate,
was esterified with 4-phenyl-1-butanol. Molecular weight of the
polymers was determined to be approximately 20000 (PEG block:
12000; modified polyaspartate block: 8000). NK105 was prepared
by facilitating the self-association of NK105 polymers and PTX.
NK105 was obtained as a freeze-dried formulation and contained
ca. 23% (ww
 1) of PTX, as determined by reversed-phase liquid
chromatography using an ODS column with mobile phase
consisting of acetonitrile and water (9:11, vv
 1) and detection
of ultraviolet absorbance at 227nm. Finally, NK105, a PTX-
incorporating polymeric micellar nanoparticle formulation with a
single and narrow size distribution, was obtained. The weight-
average diameter of the nanoparticles was approximately 85nm
ranging from 20 to 430nm (Figure 1B).
Pharmacokinetics and pharmacodynamics of NK105
Colon 26-bearing CDF1 mice were given a single i.v. injection of
PTX 50 or 100mgkg
 1, or of NK105 at an equivalent dose of PTX.
Subsequently, the time-course changes in the plasma and tumour
levels of PTX were determined in the PTX and NK105 adminis-
tration groups (Figure 2); furthermore, the pharmacokinetic
parameters of each group were also determined (Table 1).
NK105 exhibited slower clearance from the plasma than PTX,
while NK105 was present in the plasma for up to 72h after
injection; PTX was not detected after 24h or later of injection. The
plasma concentration at 5min (C5min) and the area under the
curve (AUC) of NK105 were 11–20-fold and 50–86-fold higher for
NK105 than for PTX, respectively. Furthermore, the half-life at the
terminal phase (t1/2z) was 4–6 times longer for NK105 than for
NK105 - polymer
Modified polyaspartate
(hydrophobic segment)
Polyethylene glycol
(hydrophilic segment)
Micelle formation
and
PTX entrapment
Polyethylene glycol
PTX
Inner core
with high hydrophobicity
NK105
3 10 32 101
Particle size (nm)
320 1013
A
B
Figure 1 Preparation and characterisation of NK105. (A) The micellar
structure of NK105 PTX was incorporated into the inner core of the
micelle. (B) The size distribution of NK105 measured by the dynamic light
scattering method. The mean diameter of an NK105 micelle was 85nm.
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Colon 26 tumours were approximately 3 and 25 times higher for
NK105 than for PTX, respectively. NK105 continued to accumulate
in the tumours until 72h after injection. The tumour PTX
concentration was higher than 10mgg
 1 even at 72h after the i.v.
injection of NK105 50 and 100mgkg
 1. On the contrary, the
tumour PTX concentrations at 72h after the i.v. administration of
free PTX 50 and 100mgkg
 1 were below detection limits and less
than 0.1mgg
 1, respectively.
In vitro cytotoxicity
NK105 was tested on 12 human tumour cell lines derived from
lung, gastric, oesophagus, colon, breast, and ovarian tumours.
Similar dose–response curves were noted for PTX and NK105
(data not shown). Furthermore, the IC50 values of NK105 were
similar to those of PTX at 48 and 72h, indicating that both NK105
and PTX showed equivalent cytotoxic activity in vitro (Table 2).
In vivo antitumour activity
BALB/c mice bearing s.c. HT-29 colon cancer tumours showed
decreased tumour growth rates after the administration of PTX
and NK105. However, NK105 exhibited superior antitumour
activity as compared with PTX (Po0.001). The antitumour activity
of NK105 administered at a PTX-equivalent dose of 25mgkg
 1 was
comparable to that obtained after the administration of free PTX
100mgkg
 1. Tumour suppression by NK105 increased in a dose-
dependent manner. Tumours disappeared after the first dosing to
mice treated with NK105 at a PTX-equivalent dose of 100mgkg
 1,
and all mice remained tumour-free thereafter (Figure 3A). In
addition, less weight loss was induced in mice, which were given
NK105 100mgkg
 1 than in those that were given the same dose of
free PTX (Figure 3B).
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Figure 2 Plasma and tumour concentrations of PTX after single i.v.
administration of NK105 or PTX to Colon 26-bearing CDF1 mice. Plasma
(A) and tumour (B) concentrations of PTX after NK105 administration at
a PTX-equivalent dose of 50mgkg
 1 (K), NK105 at a PTX-equivalent
dose of 100mgkg
 1 (m), PTX 50mgkg
 1 (J) and PTX 100mgkg
 1 (n).
Table 1 Pharmacokinetic parameters for the plasma and tumour concentrations of paclitaxel after single i.v. administration of NK105 and PTX to Colon
26-bearing CDF1 mice
Treatment Dose (mgkg
 1) C5min (lgml
 1) t1/2z (h) AUC0–t (lghml
 1) AUC0 inf. (lghml
 1)C L tot (mlhkg
 1) Vss (mlkg
 1)
Plasma
PTX 50 59.32 0.98 90.2
a 91.3 547.6 684.6
PTX 100 157.67 1.84 309.0
b 309.0 323.6 812.2
NK105 50 1157.03 5.99 7860.9
c 7862.3 6.4 46.4
NK105 100 1812.37 6.82 15565.7
c 15573.6 6.4 54.8
Cmax (lgml
 1) Tmax (h) t1/2z (h) AUC0–t (lghml
 1) AUC0–inf. (lghml
 1)
Tumour
PTX 50 12.50 2.0 7.02 120.8
b 133.0
PTX 100 28.57 0.5 8.06 330.4
c 331.0
NK105 50 42.45 24.0 35.07 2360.1
c 3192.0
NK105 100 71.09 6.0 73.66 3884.9
c 7964.5
i.v.¼intravenous; C5min¼plasma concentration at 5min; t1/2z¼half-life at the terminal phase; AUC¼area under the curve; CLtot¼total body clearance; Vss¼volume of
distribution at steady state; Tmax¼time of maximum concentration; PTX¼paclitaxel. Parameters were calculated from the mean value of three or two mice by
noncompartmental analysis.
aAUC0-6h.
bAUC0–24h.
cAUC0–72h.
Table 2 IC50 values (mM) of PTX and NK105 in various cell lines
48h 72h
Cancer Cell line NK105 PTX NK105 PTX
Oesophageal cancer TE-1 41.0 41.0 0.01 0.02
TE-8 0.02 0.02 0.01 0.01
Lung cancer PC-14 0.01 0.01 0.01 0.01
PC-14/TXT 0.15 0.09 0.08 0.06
H460 ND ND 0.03 0.01
Breast cancer MCF-7 41.0 41.0 0.01 0.01
Stomach cancer MKN-28 0.03 0.03 0.01 0.21
MKN-45 0.02 0.07 0.01 0.02
Colon cancer DLD-1 0.95 0.26 0.29 0.20
HT-29 0.01 0.01 0.01 0.01
HCT116 ND ND 0.03 0.01
Ovarian cancer MCAS 0.01 0.01 0.01 0.01
OVCAR-3 41.0 41.0 41.0 41.0
Pancreatic cancer AsPC-1 ND ND 0.02 0.02
PAN-9 ND ND 0.03 0.02
PAN-3 ND ND 0.010 0.004
PTX¼paclitaxel; ND¼not done.
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Treatment with PTX has resulted in cumulative sensory-dominant
peripheral neurotoxicity in humans, characterised clinically by
numbness and/or paraesthesia of the extremities. Pathologically,
axonal swelling, vesicular degeneration, and demyelination were
observed. We, therefore, examined the effects of free PTX and
NK105 using both electrophysiological and morphological
methods.
Prior to drug administration, there were no significant
differences in the amplitude of caudal sensory nerve action
potential (caudal SNAP) between two drug administration groups.
On day 6 after the last dosing (at week 6), the amplitude of the
caudal SNAP in the control group increased in association with rat
maturation. The amplitude was significantly smaller in the PTX
group than in the control group (Po0.01), while the amplitude was
significantly larger in the NK105 group than in the PTX group
(Po0.05) and was comparable between the NK105 group and the
control group (Figure 4A). Histopathological examination of
longitudinal paraffin-embedded sections of the sciatic nerve 5
days after the sixth weekly injection revealed degenerative changes.
The NK105 administration group showed only a few degenerative
myelinated fibres in contrast to the PTX administration group,
which indicated markedly more numerous degenerative myeli-
nated fibres (Po0.001) (Figure 4B and C) and Table 3.
DISCUSSION
A pharmacokinetic study revealed that the plasma AUC of NK105
was approximately 90-fold higher than that of free PTX in the
present rodent models. Prolonged circulation of NK105 in the
blood due to the EPR effect was associated with a significant
increase in the tumour AUC. In fact, the tumour AUC of NK105
was approximately 25-fold higher than that of free PTX
(Figure 2B). In mice, accordingly, NK105 exhibited stronger
antitumour activity than free PTX (Figure 3A). However, it is still
debatable whether or not the enhanced accumulation of an
anticancer drug into a tumour is sufficient in leading the drug to
exert its antitumour activity in vivo.
Jain et al have reported that the convective passage of large drug
molecules into the core of solid tumours could be impeded by
abnormally high interstitial pressures in solid tumours. However,
they also admitted that low-molecular-weight anticancer agents
might be harmful to normal organs because they can leak out of
normal blood vessels freely; they finally concluded that one useful
strategy for evading the barriers to drug dispersion would be to
inject patients with drug carriers, such as liposomes, filled with
low-molecular-weight drugs (Jain, 1994). In this case, liposomes
should have sufficient time to exit from the site of tumour blood
vessel leakage and to accumulate at reasonably high dose levels in
the surrounding interstitium. Subsequently, low-molecular-weight
drugs packed within liposomes should be released gradually so
that they can be dispersed throughout the tumour. However,
Unezaki et al have used fluorescence-labelled PEG-liposomes and
described that the area of highest fluorescence was located outside
tumour vessels, almost all around the vessel wall, even 2 days after
drug injection (Unezaki et al, 1996). Therefore, the study suggested
that although PEG-liposomes can be delivered effectively to a solid
tumour via the EPR effect, the formulation would not be
distributed sufficiently to cancer cells distant from tumour vessels
because liposomes are too large to scamper about in the tumour
interstitium. Liposomes have been suggested to be too stable to
allow the drug therein to be released easily. Therefore, PEG-
liposomes have been speculated to be not so effective against
cancers in which the tumour vessel network is irregular and loose
because of an abundant collagen-rich matrix. Such cancers include
scirrhous cancer of the stomach and pancreatic cancer. In fact,
Doxil
s, a PEG-liposomal DXR, is known to be effective clinically
against ovarian cancer and breast cancer, both of which are
characterised by a high density of tumour microvessels; however,
the drug is not effective against stomach cancer and pancreatic
cancer (Muggia, 2001).
There are several possible reasons why NK105 exhibited higher
antitumour activity in the present study as compared with free
PTX: (1) since NK105 is very stable in the circulation and exhibits
a markedly higher plasma AUC than free PTX, it accumulates
better in tumour tissue than does free PTX due to the EPR effect;
(2) NK105 is relatively small in size (85nm) as compared with
Doxil (100nm), thus explaining its more uniform distribution in
tumour tissue and its greater accumulation in cancer cells
throughout cancer tissue. Savic et al (2003) have recently reported
that polymeric micelles could internalise into cells to localise in
several cytoplasmic organelles; and (3) a polymeric micelle carrier
system for a drug has the potential to allow the effective sustained
release of the drug inside a tumour following the accumulation of
micelles into tumour tissue. Regarding NK105 in particular, this
sustained release begins at a PTX-equivalent dose of o1mgml
 1
(data not shown). Consequently, released PTX becomes distributed
throughout tumour tissue and internalises into cancer cells to kill
them.
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Figure 3 Relative changes in HT-29 tumour growth rates in nude mice.
(A) Effects of PTX (open symbols) and NK105 (closed symbols). PTX and
NK105 were injected i.v. once weekly for 3 weeks at PTX-equivalent doses
of 25mgkg
 1 (&, ’), 50mgkg
 1 (n, m), and 100mgkg
 1 (J, K),
respectively. Saline was injected to control animals (K). (B) Changes in
relative body weight. Data were derived from the same mice as those used
for the present study.
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been developed. Among them, clinical trials are currently ongoing
for the following drugs: CT-2103, polyglutamate-conjugated PTX
(Singer et al, 2003); ABI-007, PTX coated with albumin (Ibrahim
et al, 2002); and Genexol-PM, PTX micelle in which PTX is simply
solubilised (Kim et al, 2004). The advantage commonly shared
with these dosage forms is that they are injectable i.v. without the
mixture of Cremophor EL and ethanol, which potentially provoke
serious allergic reactions. The block copolymer used for forming
NK105 micellar nanoparticles is nonimmunogenic and is injectable
i.v. without Cremorphor EL and ethanol. Therefore, this dosage
form is expected to possess a clinical advantage, which is similar to
that of the above PTX dosage forms. Now, what is the difference
between NK105 and other PTX dosage forms? ABI-007 and
Genexol-PM were found to have the AUC and tumour AUC,
which are nearly comparable or rather slightly lower than those of
free PTX. Furthermore, the plasma AUC and tumour AUC are
11.5- and 11.8-fold higher, respectively, for CT-2103 than for free
PTX, but they are markedly low as compared with those of NK105.
Respective studies have employed proper tumours and proper
rodent models. However, NK105 was forecasted to have markedly
high plasma and tumour AUC as compared with those of other
PTX dosage forms.
Regarding the toxicity profiles, the repeated administration of
NK105 to rats at 7-day intervals produced less toxic effects on
peripheral nerves than free PTX. This reduced the neurotoxicity of
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Figure 4 Incorporation of PTX into polymeric micelles diminishes neurotoxicity. (A) Effects of PTX or NK105 on the amplitude of rat caudal sensory
nerve action potentials as examined 5 days after weekly injections for 6 weeks. Rats (n¼14) were injected with NK105 (’) or PTX (&) at a PTX-
equivalent dose of 7.5mgkg
 1. Glucose (5%) was also injected in the same manner to animals in the control group (’). *Po0.05, **Po0.01. (B)
Histopathological changes in the sciatic nerve of rats. Degenerating myelinated nerve fibres (arrow) were examined in the longitudinal section of the sciatic
nerve (H & E) 5 days after weekly injections for 6 weeks with 5% glucose (a), PTX (b), and NK105 (c) at a PTX-equivalent dose of 7.5mgkg
 1.
Magnification,  100 (upper) and  400 (lower). (C) Incidences of degenerating myelinated nerve fibres in rats treated with PTX or NK105. NK105 or PTX
was administered i.v. at a weekly dose of 7.5mgkg
 1 for 6 consecutive weeks to female rats. The degenerating myelinated fibre score was defined as follows:
 , no degenerative changes; þ/ , very slight degree of the degenerative changes (scattered, single fibres affected); þ, slight degree of degenerative
changes (scattered small groups of degenerative myelinated fibres); þþ, moderate degree of degenerative changes (disseminated degenerative myelinated
fibres); þþþ, marked degree of degenerative changes (confluent groups of affected fibres).
aPo0.001 vs vehicle-treated animals.
bPo0.001 vs PTX-
treated animals.
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histopathological and physiological methods and was probably
attributable to the less distribution of PTX into normal neural
tissue following NK105 administration, since the volume of
distribution at steady state (Vss) of NK105 was 100-fold lower
than that of free PTX. Regarding bone marrow toxicity, there was
no difference between PTX and NK105 when 37.5mgkg
 1 of PTX-
equivalent dose was administered to rats weekly for 4 consecutive
weeks (data not shown). These data indicate that NK105 warrants a
clinical evaluation.
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d 14 8 2 4
PTX¼paclitaxel. Vehicle, NK105 or PTX was administered i.v. at a weekly dose of
7.5mgkg
 1 for 6 consecutive weeks to female rats.
aTotal number of animals
accounted for that experimental condition.
bDegenerating myelinated fibre score was
defined as follows:  , no degenerative changes; +/ , very slight degree of the
degenerative changes (scattered, single fibres affected); +, slight degree of
degenerative changes (scattered small groups of degenerative myelinated fibers);
++, moderate degree of degenerative changes (disseminated degenerative
myelinated fibers); +++, marked degree of degenerative changes (confluent groups
of affected fibres).
cPo0.001 vs vehicle-treated animals.
dPo0.001 vs PTX-treated
animals.
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